China Cord Blood Corporation (CO) Receives Daily Media Sentiment Score of 0.17
Media stories about China Cord Blood Corporation (NYSE:CO) have trended somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. China Cord Blood Corporation earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 46.3201797655422 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have effected Accern Sentiment’s analysis:
- China Cord Blood Corporation (CO) versus The Competition Financial Review (americanbankingnews.com)
- Umbilical Cord Blood Banking Market to Exhibit a Healthy Growth of 6.1% CAGR Between 2014-2020 (sbwire.com)
- China Cord Blood Corp. – Value Analysis (NYSE:CO) : September 22, 2017 (finance.yahoo.com)
- China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 7, 2017 (finance.yahoo.com)
- China Cord Blood Corp. breached its 50 day moving average in a Bearish Manner : CO-US : September 21, 2017 (finance.yahoo.com)
China Cord Blood Corporation (NYSE CO) traded down 2.78% during midday trading on Friday, reaching $11.18. 513,886 shares of the company’s stock traded hands. China Cord Blood Corporation has a one year low of $4.27 and a one year high of $14.95. The stock’s 50 day moving average price is $12.58 and its 200-day moving average price is $9.21. The stock has a market cap of $1.27 billion, a PE ratio of 35.72 and a beta of 0.91.
China Cord Blood Corporation (NYSE:CO) last released its quarterly earnings data on Wednesday, August 23rd. The medical research company reported $0.09 EPS for the quarter. China Cord Blood Corporation had a return on equity of 8.64% and a net margin of 22.07%. The company had revenue of $33.07 million during the quarter. Equities analysts predict that China Cord Blood Corporation will post $0.15 earnings per share for the current year.
Separately, BidaskClub raised shares of China Cord Blood Corporation from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 1st.
About China Cord Blood Corporation
China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.
Receive News & Ratings for China Cord Blood Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood Corporation and related companies with MarketBeat.com's FREE daily email newsletter.